source
- Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitorA biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse mergers to take their experimental medicines ont…Endpoints · 6h ago↗ source
- Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationAfter keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…Fierce Biotech · 7h ago↗ source
- STAT+: Why benchmarking clinical LLMs from OpenEvidence, Doximity is complicatedIn this edition of AI Prognosis: A conversation about benchmarking leading clinical chatbots, investor view on AI in biopharma, and more.